Byk Gulden, which is now able to market its proton pump inhibitor pantoprazole without prosecution from competitor Astra of Sweden (Marketletter June 17 and page 28), is forecasting that 1996 sales of its product will reach at least 160 million Deutschemarks ($105.2 million). The firm is also saying that it expects to reach the "profitability zone" at the end of the year. By the year 2000, turnover of pantoprazole will be around 500 million marks.
Sales will come mainly from Europe, where Astra's product Losec (omeprazole) has a 40% market share. An Astra spokesperson said Byk Gulden would not get its product on the market in the USA before 1999. In 1996, Losec sales are expected to be 20 billion Swedish kroner ($3 billion).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze